This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Albert-Ludwigs-Universitaet Freiburg. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Susanne Schultze-Seemann: Innovator in Chimeric Antigen Receptors
Introduction
Susanne Schultze-Seemann is a prominent inventor based in Merzhausen, Germany. She has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs) that target prostate-specific membrane antigen (PSMA). Her innovative work aims to enhance the effectiveness of cancer treatments.
Latest Patents
Susanne holds a patent for a novel chimeric antigen receptor that specifically binds to PSMA. This invention relates to a method of manufacturing high-quality CAR T cell products through transfection and/or transduction of T cells. The technology allows for effective in vivo tumor treatment, either alone or in combination with various pharmaceutical drugs, including chemotherapies and biopharmaceuticals.
Career Highlights
Susanne Schultze-Seemann is affiliated with the Albert-Ludwigs-Universität Freiburg, where she conducts her research. Her work has been instrumental in advancing the field of CAR T cell therapy, providing new avenues for treating prostate cancer.
Collaborations
One of her notable collaborators is Toni Cathomen, who works alongside her in the research and development of innovative therapeutic solutions.
Conclusion
Susanne Schultze-Seemann's contributions to the field of immunotherapy through her patented innovations highlight her role as a leading inventor in cancer treatment. Her work continues to pave the way for advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile